Budget Impact and Clinical Outcomes of a Molecular Signature to Inform TNFi Treatment Selection in Commercial Patients with Rheumatoid Arthritis
Martin Bergman, MD; Erin Connolly-Strong, PhD; Alyssa Guidoboni, MScM; Alix Arnaud, MsC
Presented at AMCP 2022 Chicago, Illinois – March 29, 2022
Introduction:
• Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation.
• With no established preference for one class of drug over the other after failure of conventional csDMARDs, current treatment strategy for RA consists of a trial-and-error approach.
• Cycling between ineffective drug treatments can lead to delays in reaching treat-to-target goals in turn risking disease progression.
• Rapid achievement of treat-to-target goals is significantly associated with lower healthcare costs, slowed disease progression, lower mortality rate, improved work function, decreased disability, decreased pain and improved quality of life.
Objective:
This analysis evaluated the budget and clinical impact of integrating MSRC testing in the treatment decision making for adults with RA who are considering starting, switching, or dose escalating with a TNFi.
Conclusion:
• The integration of the MSRC precision medicine tool in the treatment of RA benefits patients and results in meaningful net savings between $11,871 and $21,188 per patient tested.
• MSRC-informed treatment improves population level response rates, decreases pharmacy spend by shifting patients away from likely ineffective and expensive therapy classes, decreases total cost of care, and decreases workplace costs for patients with RA.